Alnylam Pharmaceuticals (ALNY) Stock Price, Quote & News

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products i...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 551 8200

Fax: 617 551 8101

Website: www.alnylam.com

Address:

675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States

sampeper Aug. 17 at 1:39 AM

$ALNY Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing https://www.theglobeandmail.com/investing/markets/stocks/IONS-Q/pressreleases/3874920/why-the-alnylam-sell-off-looks-overdone-and-what-investors-are-missing/

0 · Reply

Olena Aug. 16 at 5:57 PM

$ALNY profitable, phase 3 this year

0 · Reply

OnlyFibs Aug. 15 at 11:19 PM

$ALNY | Alnylam Pharmaceuticals | Healthcare 🧬 Heavy buyer volume flooding into $ALNY as price prints a decisive higher low off its $197.90 macro demand floor! 📈⚡ Alnylam leads global commercialization of RNAi therapeutics powered by its blockbuster AMVUTTRA franchise 🏥 Profitability & Fundamentals: Commercial biopharma powerhouse generating $1.29B Q2 net revenue (+67% YoY) with $3.3B in liquid cash reserves. Technicals: 8h chart highlights a sharp V-bottom higher-low reversal backed by consistent buying volume 🎯 Price reclaimed $220.00 and is coiling for a trendline breakout toward $272.00 and $315.00 supply. Bull Key Levels: $222.00 🐂 🔥 | Confirm: $245.00 🐂 🚀 | Extension: $272.00 🐂 💥 Bear Key Levels: $205.00 🐻 ⚠️ | Confirm: $197.90 🐻 📉 | Extension: $180.00 🐻 🚨 Stop Loss: $201.50 🛑 Targets: $272.00 / $315.00 💰 🍺 OVERALL: 🐂 BULLISH 🐂 #hovdid

0 · Reply

jewell69 Aug. 14 at 6:17 PM

$ALNY I know, I know 30 bucks. I get it. short leash. very very very rare disease 08/14/2026 Sell Edit cost basis method ALNY ALNYLAM PHARMACEUTICALS 18 $227.80 $0.08 $4,100.32 More 08/13/2026 Buy ALNY ALNYLAM PHARMACEUTICALS 18 $226.12 -$4,070.16

0 · Reply

JimmyOcarri Aug. 13 at 11:03 PM

$ALNY nice `

0 · Reply

Fingerlickengood Aug. 13 at 7:17 PM

$CDXS It's quiet possible Aurisco is indirectly using Codexis' technology through a relationship they formed years ago with Porton Pharma of China under John Nichols leadership. I think it's VERY compelling that Aurisco has obtained licensing to manufacture both Inclisiran and Vutrisiran from $ALNY . Now USFDA has approved their CDMO facility to manufacture both for the 'generic market'. https://www.pharmafocusasia.com/interviews/codexis-porton-partnership

0 · Reply

jewell69 Aug. 13 at 6:00 PM

$ALNY trying 2 by 18 at 226.12. yes u read it correctly. thing fell tons 3 weeks ago. beware ! potential patient population is only 38,000 people in the usa. sort of reminds me of $SRPT Date Transaction Type Symbol Description Quantity Price Fees & Comm Amount 07/27/2026 Sell ALNY ALNYLAM PHARMACEUTICALS 29 $282.96 $0.18 $8,205.66 More 07/24/2026 Sell ALNY ALNYLAM PHARMACEUTICALS 11 $271.92 $0.06 $2,991.06 More 07/22/2026 Buy ALNY ALNYLAM PHARMACEUTICALS 11 $265.10 -$2,916.10 More 07/21/2026 Buy ALNY ALNYLAM PHARMACEUTICALS 8 $272.14 -$2,177.12 More 07/20/2026 Sell ALNY ALNYLAM PHARMACEUTICALS 8 $272.73 $0.04 $2,181.80 More 07/17/2026 Buy ALNY ALNYLAM PHARMACEUTICALS 8 $271.80 -$2,174.40

1 · Reply

ConsistentSpike Aug. 13 at 5:31 PM

$ALNY https://www.tipranks.com/news/raymond-james-is-betting-big-on-these-2-strong-buy-stocks

0 · Reply

SahreIn Aug. 12 at 8:26 PM

$ALNY nice price movement .. should break 230 in a week

0 · Reply

Fingerlickengood Aug. 12 at 11:20 AM

$CDXS $MRK $ALNY $BMY The fact they 'emphasized and reiterated' this during their confrence call, specifically that it has become a topic 'of interest' to many potential and existing customers, is telling!

0 · Reply

ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Jul 30, 2026, 8:30 AM EDT - 19 days ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 19 days ago

Alnylam Pharmaceuticals Earnings release: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 19 days ago

Alnylam Pharmaceuticals Quarterly report: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 19 days ago

Alnylam Pharmaceuticals Slides: Q2 2026

Jul 30, 2026, 8:00 AM EDT - 20 days ago

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

Jul 16, 2026, 8:00 AM EDT - 4 weeks ago

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Jul 15, 2026, 3:30 AM EDT - 5 weeks ago

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Jul 9, 2026, 7:38 AM EDT - 5 weeks ago

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

AZN IONS

Jun 25, 2026, 11:00 AM EDT - 7 weeks ago

Alnylam Pharmaceuticals Transcript: Study update

Jun 25, 2026, 11:00 AM EDT - 7 weeks ago

Alnylam Pharmaceuticals Slides: Study update

Jun 25, 2026, 9:00 AM EDT - 7 weeks ago

Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

Jun 17, 2026, 12:30 PM EDT - 2 months ago

The Healthcare M&A Wave

ABT AMGN AMRX ANTX AZN BDX BEAM

Jun 12, 2026, 9:00 AM EDT - 2 months ago

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

Jun 10, 2026, 7:47 AM EDT - 2 months ago

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Jun 9, 2026, 11:20 AM EDT - 2 months ago

Alnylam Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 5:06 PM EDT - 2 months ago

Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500

ALAB BE RDDT

Jun 3, 2026, 6:05 PM EDT - 2 months ago

Alnylam, Inceptive sign up to $2 billion AI drug discovery deal

Jun 3, 2026, 4:45 PM EDT - 2 months ago

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

May 20, 2026, 10:30 AM EDT - 3 months ago

Alnylam Pharmaceuticals Transcript: AGM 2026

May 19, 2026, 8:30 AM EDT - 3 months ago

Alnylam Issues 2025 Corporate Responsibility Report

May 13, 2026, 1:40 PM EDT - 3 months ago

Alnylam Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 2:30 AM EDT - 3 months ago

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

May 7, 2026, 8:00 AM EDT - 3 months ago

Alnylam to Webcast Presentations at Upcoming Investor Conferences

May 4, 2026, 8:30 AM EDT - 3 months ago

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Alnylam Pharmaceuticals Quarterly report: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Alnylam Pharmaceuticals Slides: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Alnylam Pharmaceuticals Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

Apr 6, 2026, 2:14 PM EDT - 4 months ago

An S&P 500 change may be imminent. These stocks are leading contenders to join the index.

IVV SPXL SPY SSO UPRO VOO FERG

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Alnylam Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Alnylam Pharmaceuticals Proxy statement: Proxy filing

Mar 30, 2026, 1:00 PM EDT - 5 months ago

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

Mar 24, 2026, 9:30 AM EDT - 5 months ago

Alnylam Pharmaceuticals Transcript: Status update

Mar 24, 2026, 9:30 AM EDT - 5 months ago

Alnylam Pharmaceuticals Press release: Status update

Mar 24, 2026, 9:30 AM EDT - 5 months ago

Alnylam Pharmaceuticals Slides: Status update

Mar 24, 2026, 9:00 AM EDT - 5 months ago

Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis

Mar 24, 2026, 7:30 AM EDT - 5 months ago

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

Mar 11, 2026, 11:55 AM EDT - 5 months ago

How Alnylam Stock Weathers Market Shocks

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Alnylam to Webcast TTR Investor Webinar

Mar 5, 2026, 9:10 AM EST - 5 months ago

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

TNYA

Mar 5, 2026, 8:30 AM EST - 5 months ago

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

TNYA

Mar 2, 2026, 9:10 AM EST - 6 months ago